BusinessPublic Health

Obesity Devices Gain From Drug Woes

1 Mins read

It is a repeated theme in the history of medtech development. Drugs represent an alluring treatment alternative, since the option to swallow a pill to deal with a problem will almost always be more attractive than any other option. Biotech products offer the potential to target the root cause of the problem. However, drugs and biotechs have enormous hurdles to proving safety and efficacy. Meanwhile, medical devices — being far more difficult to use than drugs and being much more symptom-oriented and less root cause-oriented than biotechs — are frequently able to more readily prove safety and efficacy. So, now, as yet another obesity drug (Orexigen’s Contrave) has been rejected by the FDA, the upside for obesity devices (with many already on the market) continues to be more promising (while biotechs are not even part of the equation here). Below is the outlook for different obesity device treatment types through 2019.

Source: “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019”, Report #S835.

To be clear, this does not say that there still isn’t enormous potential for obesity drugs — indeed, reports that the obesity drug market is dead are naively premature, even with recent FDA drug rejections — since the demand for drugs remains high even if obesity incidence rates were not skyrocketing or even if there was not already an enormous and growing obesity device market as shown above. The precedence in clinical practice, the regulatory environment and the healthcare market for obesity devices simultaneously represent the opportunity and challenge for obesity drugs to succeed.

183 posts

About author
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Related posts

5 Creative Ways to Advertise in the Healthcare Industry

4 Mins read
The healthcare industry is a dynamic one, with medical innovations, patient needs, financial obligations and changing regulations driving caregivers and administrators to…
Health carePolicy & LawPublic HealthUncategorized

How Personal Injury Lawsuits Can Affect Your Relationship

3 Mins read
Accidents happen at the most unexpected time and place. When it does, victims suffer a personal injury that can have a long-lasting…
Covid-19Health careHospital AdministrationNursingPublic Health

The Future Of Nursing In A Post-Pandemic World

3 Mins read
Right now, it feels like life and work will never be the same again. Public spaces are severely restricted, lots of people…